Compare RES & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | VCEL |
|---|---|---|
| Founded | 1984 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1995 | 1996 |
| Metric | RES | VCEL |
|---|---|---|
| Price | $7.61 | $34.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.64 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.2M | 633.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | 0.15 | ★ 0.32 |
| Revenue | ★ $41,919,000,000.00 | $276,259,000.00 |
| Revenue This Year | $3.29 | $19.40 |
| Revenue Next Year | $4.05 | $18.24 |
| P/E Ratio | ★ $49.77 | $106.97 |
| Revenue Growth | ★ 2216.21 | 16.45 |
| 52 Week Low | $4.18 | $28.95 |
| 52 Week High | $7.53 | $45.97 |
| Indicator | RES | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 50.65 |
| Support Level | $5.19 | $31.24 |
| Resistance Level | N/A | $34.77 |
| Average True Range (ATR) | 0.30 | 1.25 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 79.22 | 37.04 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.